Abstract
The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance vs placebo in MM patients (pts) post-autologous stem cell transplant (ASCT) (Dimopoulos et al, Lancet 2019). Ixazomib maintenance was well tolerated with a low rate of discontinuation due to AEs. We report additional safety data from TOURMALINE-MM3 to inform AE management recommendations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
